欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 1999, Vol. 4 ›› Issue (4): 325-330.

• 论著 • 上一篇    下一篇

临床联合用药方案的定量设计1

郑青山   

  1. 中国科学技术大学生命科学学院,合肥 230027
  • 收稿日期:1999-10-29 发布日期:2020-11-27

Quantitative design of clinical scheme of combinatiou drug therapy1

ZHENG Qing Shan   

  1. School of Life Science, Universily of Science and Technology of China, Hefei 230027, China
  • Received:1999-10-29 Published:2020-11-27

摘要: 目的 应用权重配方法,从多药物多剂量中优选临床联合用药方案,并以一个定量设计的范例说明其可行性。方法 根据临床实际, 虚拟药1,药2和药3联用治疗儿童缺铁性贫血2wk。各药分为5~6个剂量水平,再均匀分布到6个组,每组6例,即构成6个联用方案。测定治疗2, 3, 4 wk时的血红蛋白升高值(△Hb),以4wk的测定值作为指标,用权重配方法进行数据分析,优化联用剂量,经确定性试验证实,从而寻找出最优化方案。结果 药1和药2都是主药,但药1 对联合药效(△Hb)的贡献值最大,其次是药2,而药3作用极弱;药1与药2间有较强的协同作用,药2和药3间有微弱的协同作用,但药3对药1有拮抗作用。重新制定联合用药方案,经确定性试验证实,将药1 和药2调整到允许的最大剂量,删除药3组成新的方案,同最大效应组比较,表明此联用方案为一优化方案。结论 权重配方法能有效地分析临床试验中各药在组方中的地位,并据此调整剂量,构成新的方案,经配方优化检验,可定量设计临床联合用药方案。

关键词: 联合 药物治疗, 药物相互作用, 药物协同作用, 药物拮抗作用, 药物剂量效应关系, 权重配方法

Abstract: Aim To show the performance of the weighted modification method in the clinical design of combination drug therapy. Methods A scheme combined by Drug1, Drug2 and Drug3 was used to treat infants with iron deficiency anemia for 2 wk in a hypothetical clinical trial. Thirty-six infants were randomly into 6 compound groups. Three drugs in the scheme were divided into 6 dose levels, which were evenly distributed to the 6 groups according to the weighted modification method. The increased Hb (△Hb) was recorded at 2, 3, 4 wk after the treatment (po). The dose-effect data at 4 wk were analyzed by the method, and then the doses in scheme were modified by the analytic result. The modified doses in the scheme would be further demonstrated.Results Drug1 and Drug2 were principal drugs, but Drug1 had larger contribution to the combined effect (△Hb) than Drug2. Drug3 had lttle effect. There was a strong synergism between Drug1 and Drug2 with the weighted coefficient (b1) =2. 636(P<0.05), and a slight synergism between Drug2 and Drug3 with bz =0.460 (P<0. 05). But there was a significant antagonism between Drug1 and Drug3 with the weighted cofficient(B) =-0.829 (P<0.05) 。The doses were adjusted to form a new scheme with Drug1 60 mg·kg-1 +Drug2 10 mg·kg-1(p) and Drug 3 was deleted from the scheme. The scheme was an optimal one confirmed by a demonstration trial.Conclusion This method is able to effectively determine important degree of drugs in combination, and to optimize their doses for designing the scheme of combination drug therapy.

Key words: combination drug therapy, drug combinations, drug interaction, program evaluation, drug dose-response relationship, weighted modification method

中图分类号: